Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines (BPMC)
NASDAQ:BPMC
Blueprint Medicines (BPMC) Stock Price & Analysis
502 Followers
BPMC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$43.89 - $110.93
Previous Close$108.55
Volume200.94K
Average Volume (3M)829.55K
Market Cap
$6.71B
Enterprise Value$6.86B
Total Cash (Recent Filing)$710.64M
Total Debt (Recent Filing)$774.12M
Price to Earnings (P/E)-22.5
Beta1.39
Next Earnings
Jul 31, 2024EPS Estimate
-$1.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.82
Shares Outstanding62,616,902
10 Day Avg. Volume866,188
30 Day Avg. Volume829,548
Standard Deviation0.14
R-Squared0.06
Alpha0.00591
Financial Highlights & Ratios
Price to Book (P/B)50.94
Price to Sales (P/S)94.46
Price to Cash Flow (P/CF)-21.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue29.61
Enterprise Value/Gross Profit28.49
Enterprise Value/Ebitda-14.53
Forecast
1Y Price Target
$110.18Price Target Upside2.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Blueprint Medicines News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBlueprint reported better-than-expected Ayvakit revenues, prompting an increase in FY24 Ayvakit guidance.
Market PotentialBlueprint increased its FY24 Ayvakit guidance early in the year, with room for future upward revisions.
Sales GrowthAyvakit sales were above consensus/Baird estimates and representing significant quarterly growth.
Bears Say
Company GuidanceUpdated guidance suggests a steep drop in patient adds for the remainder of the year, which is hard to reconcile with results and qualitative comments.
Financial Performance4Q23 collaboration revenue was down 61% year over year, following the termination of the Roche/Gavreto collaboration.
Market CompetitionCompetitive landscape shows other companies also developing mast cell-driven disease therapies, posing potential challenges to Blueprint's market position.
---
Ownership Overview
16.87% Insiders
45.12% Mutual Funds
18.88% Other Institutional Investors
19.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BPMC FAQ
What was Blueprint Medicines’s price range in the past 12 months?
Blueprint Medicines lowest stock price was $43.89 and its highest was $110.93 in the past 12 months.
What is Blueprint Medicines’s market cap?
Currently, no data Available
When is Blueprint Medicines’s upcoming earnings report date?
Blueprint Medicines’s upcoming earnings report date is Jul 31, 2024 which is in 83 days.
How were Blueprint Medicines’s earnings last quarter?
Blueprint Medicines released its earnings results on May 02, 2024. The company reported $1.45 earnings per share for the quarter, beating the consensus estimate of -$1.666 by $3.116.
Is Blueprint Medicines overvalued?
According to Wall Street analysts Blueprint Medicines’s price is currently Undervalued.
Does Blueprint Medicines pay dividends?
Blueprint Medicines does not currently pay dividends.
What is Blueprint Medicines’s EPS estimate?
Blueprint Medicines’s EPS estimate is -$1.29.
How many shares outstanding does Blueprint Medicines have?
Blueprint Medicines has 62,616,900 shares outstanding.
What happened to Blueprint Medicines’s price movement after its last earnings report?
Blueprint Medicines reported an EPS of $1.45 in its last earnings report, beating expectations of -$1.666. Following the earnings report the stock price went up 12.798%.
Which hedge fund is a major shareholder of Blueprint Medicines?
Among the largest hedge funds holding Blueprint Medicines’s share is Woodline Partners LP. It holds Blueprint Medicines’s shares valued at 75M.
---
Blueprint Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$110.18 (2.83% Upside)
$110.18 (2.83% Upside)
Blogger Sentiment
Bullish
BPMC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 144.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
93.04%
12-Months-Change
Fundamentals
Return on Equity
-79.53%
Trailing 12-Months
Asset Growth
-14.90%
Trailing 12-Months
Company Description
Blueprint Medicines
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
---
BPMC Company Deck
---
BPMC Earnings Call
Q1 2024
0:00 / 0:00
---
BPMC Stock 12 Month Forecast
Average Price Target
$110.18
▲(2.83% Upside)
Technical Analysis
Best Analysts Covering BPMC
1 Year
1 Year Success Rate
11/14 ratings generated profit
1 Year Average Return
+38.91%
reiterated a buy rating 6 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +38.91% per trade.
---